2940 North Highway 360
About NEOS Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. Contact: HR@NeosTX.com.
91 articles with NEOS Therapeutics
Neos Therapeutics to Host Fourth Quarter and Year-End 2018 Financial and Operating Results Conference Call on March 14th, 2019
Neos Therapeutics, Inc. today announced that it will report its fourth quarter and year-end 2018 financial results prior to the opening of U.S. financial markets on Thursday, March 14, 2019.
Neos Therapeutics, Inc. announced the appointment of James Robinson to its board of directors.
Neos Therapeutics, Inc. announced that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA, Inc. to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT® extended-release orally disintegrating tablets and Teva's Abbreviated New Drug Application filed with the U.S. Food and Drug Administration to market a generic version of that product.
Strategic assessment leads to new salesforce structure and is expected to accelerate path to profitability
Company to host conference call today at 8:30am ET
Neos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 17,391,304 shares of its common stock at a price to the public of $2.30 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos.
Neos Therapeutics, Inc. today announced that it has commenced an underwritten public offering of its common stock
Neos Therapeutics, Inc. today announced that it will report third quarter 2018 financial results prior to the opening of U.S. financial markets on Friday, November 9, 2018.
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
Neos Therapeutics, Inc. today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release Orally-Disintegrating Tablets, at the 65th Annual Meeting of the American Academy of Child & Adolescent Psychiatry(AACAP), being held October 22-27, 2018 at the Washington State Convention Center in Seattle, Washington.
Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that Jerry McLaughlin, Chief Executive Officer of Neos Therapeutics, will present a company overview at the upcoming Wells Fargo 2018 Healthcare Conference on Wednesday, September 5, 2018 at 2:25 p.m. ET in Boston, MA.
Here’s a look at eight biopharma companies with upcoming catalysts.
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
[08-November-2017] INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closin
Total product revenues were $6.7 million for the three months ended September 30, 2017, compared to $1.6 million for the same period in 2016.
Management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
PDL BioPharma today issued the following statement in response to the Neos Board of Directors' rejection of PDL's October 26 proposal to acquire Neos for $10.25 per share in cash.
NEOS Therapeutics today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma to acquire all of the outstanding shares of Neos for $10.25 per share in cash.
Neos Therapeutics, Inc. today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. to acquire all of the outstanding shares of Neos for $10.25 per share in cash.